IsoRay, Inc. and SubsidiariesConsolidated Statements of Operations(Unaudited) Three months ended Six months ended December 31, December 31, 2012 2011 2012 2011 ----------- ----------- ----------- -----------Product sales $ 975,457 $ 1,228,655 $ 2,031,689 $ 2,442,072Cost of product sales 1,134,083 1,029,757 2,210,740 2,176,832 ----------- ----------- ----------- ----------- Gross profit / (loss) (158,626) 198,898 (179,051) 265,240 ----------- ----------- ----------- -----------Operating expenses: Research and development expenses 149,176 189,661 290,648 440,975 Research and development reimbursement - - - (50,000) Sales and marketing expenses 322,094 304,120 638,150 618,538 General and administrative expenses 469,559 497,168 1,114,412 1,150,095 ----------- ----------- ----------- ----------- Total operating expenses 940,829 990,949 2,043,210 2,159,608 ----------- ----------- ----------- -----------Operating loss (1,099,455) (792,051) (2,222,261) (1,894,368) ----------- ----------- ----------- -----------Non-operating income (expense): Interest income 128 268 272 455 Change in fair value of warrant derivative liability (55,000) 166,000 74,000 166,000 Financing and interest expense - (2,962) (6) (3,056) ----------- ----------- ----------- ----------- Non-operating income / (expense), net (54,872) 163,306 74,266 163,399 ----------- ----------- ----------- ----------- Net loss (1,154,327) (628,745) (2,147,995) (1,730,969) Preferred stock dividends (2,658) (2,658) (5,316) (5,316) ----------- ----------- ----------- ----------- Net loss applicable to common shareholders $(1,156,985) $ (631,403) $(2,153,311) $(1,736,285) =========== =========== =========== ===========Basic and diluted loss per share $ (0.03) $ (0.02) $ (0.06) $ (0.06) =========== =========== =========== ===========Weighted average shares used in computing net loss per share:Basic and diluted 34,604,605 28,593,845 34,238,401 27,540,492 =========== =========== =========== ===========
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which
is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington
company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join
us on Facebook/Isoray. Follow us on Twitter@Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, future demand for IsoRay's existing and planned products, whether revenue and other financial metrics will improve in future periods, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether IsoRay will be able to generate sales in the U.S. and internationally, whether additional studies will be published with favorable outcomes from treatment with Cesium-131, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, whether later studies and protocols support the findings of the initial studies, success of future research and development activities, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay's ability to successfully manufacture, market and sell its products, whether institutions will receive all required state and foreign regulatory approvals and licenses to use IsoRay's products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
Worldwide Financial
(954) 360-9998
Info@wwfinancial.com
